Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Accenture
Chubb
McKinsey
Daiichi Sankyo
Teva

Generated: June 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOLIFENACIN SUCCINATE

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for Solifenacin Succinate

Trial ID Title Status Sponsor Phase Summary
NCT00189800 A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder Completed Astellas Pharma Korea, Inc. Phase 3 The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.
NCT00189800 A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder Completed Astellas Pharma Inc Phase 3 The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.
NCT00333112 A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. Completed Astellas Pharma Inc Phase 4 A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00337558 A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) Completed Astellas Pharma Europe B.V. Phase 4 This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.
NCT00337558 A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) Completed Astellas Pharma Inc Phase 4 This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.
NCT00368706 A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Completed Astellas Pharma Inc Phase 3 To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00454740 Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder Completed Astellas Pharma Inc Phase 3 To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Solifenacin Succinate

Condition Name

Condition Name for Solifenacin Succinate
Intervention Trials
Overactive Bladder 15
Urinary Bladder, Overactive 14
Lower Urinary Tract Symptoms 5
Urinary Incontinence 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Solifenacin Succinate
Intervention Trials
Urinary Bladder, Overactive 32
Prostatic Hyperplasia 6
Hyperplasia 6
Lower Urinary Tract Symptoms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Solifenacin Succinate

Trials by Country

Trials by Country for Solifenacin Succinate
Location Trials
United States 260
Canada 20
United Kingdom 19
Netherlands 17
Belgium 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Solifenacin Succinate
Location Trials
New York 13
Florida 11
Texas 10
Pennsylvania 9
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Solifenacin Succinate

Clinical Trial Phase

Clinical Trial Phase for Solifenacin Succinate
Clinical Trial Phase Trials
Phase 4 18
Phase 3 16
Phase 2 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Solifenacin Succinate
Clinical Trial Phase Trials
Completed 42
Unknown status 2
Withdrawn 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Solifenacin Succinate

Sponsor Name

Sponsor Name for Solifenacin Succinate
Sponsor Trials
Astellas Pharma Inc 21
Astellas Pharma Europe B.V. 16
Astellas Pharma Korea, Inc. 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Solifenacin Succinate
Sponsor Trials
Industry 46
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Fish and Richardson
Mallinckrodt
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.